Deutsche Bank analyst Imron Zafar downgraded ShockWave Medical to Hold from Buy with a price target of $335, up from $270, after Johnson & Johnson (J&J) announced a definitive agreement to acquire Shockwave for $335 per share. Given the proprietary nature of Shockwave’s portfolio, the firm does not anticipate any FTC concerns. It exacts the deal to be completed around the mid-2024 timeframe.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- ShockWave Medical downgraded to Market Perform from Outperform at Leerink
- ShockWave Medical downgraded to Hold from Buy at Canaccord
- ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- M&A News: Johnson & Johnson (NYSE:JNJ) Enters Into $13.1B Shockwave Medical Deal